Dudediligence.

Anavex Life Sciences Corp

AVXLNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

92.7M

on 2026-06-30, from 83.6M on 2024-03-31 10-Q ↗

25M50M75M100MMar2024JunSepDecMar2025JunSepDecMar2026Jun

Newest

$300.0M

S-3 of 2025-07-14. 1 prospectus supplement filed under it since. S-3 ↗

$150.0M

TD Securities (USA), agreement of 2025-07-28. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗

Warrants

10K

Warrants of every class as tagged in the XBRL facts on 2026-03-31. 10-Q ↗

Cash

16.2 quarters

$118.3M on 2026-06-30 ÷ $7.3M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 2 of its filings are not read yet.